We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+42.82%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$417M
AUM Growth
+$95.9M
Cap. Flow
-$11.1M
Cap. Flow %
-2.67%
Top 10 Hldgs %
49.63%
Holding
82
New
7
Increased
14
Reduced
24
Closed
6

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$4.86M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$4.37M
3
BHVN icon
Biohaven
BHVN
+$4.16M
4
SLRN
ACELYRIN
SLRN
+$3.11M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.58M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$8.98M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.02M
3
NRIX icon
Nurix Therapeutics
NRIX
+$4.38M
4
CYTK icon
Cytokinetics
CYTK
+$2.88M
5
AUTL
Autolus Therapeutics
AUTL
+$2.81M

Sector Composition

Rank Sector Weight
1 Healthcare 85.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
51
MacroGenics
MGNX
$257M
$1.46M 0.35%
152,250
-106,246
-41% -$734K
RGLS
52
DELISTED
Regulus Therapeutics
RGLS
$1.42M 0.34%
1,111,049
– –
ARGX icon
53
argenx
ARGX
$54.1B
$1.37M 0.33%
+3,600
New +$1.68M
GOSS icon
54
Gossamer Bio
GOSS
$87M
$1.35M 0.32%
1,476,052
– –
CGEM icon
55
Cullinan Oncology
CGEM
$1.14B
$1.3M 0.31%
127,284
– –
AUTL
56
Autolus Therapeutics
AUTL
$562M
$1.23M 0.29%
191,070
-737,183
-79% -$2.81M
STRO icon
57
Sutro Biopharma
STRO
$421M
$1.21M 0.29%
28,308
– –
IMTX icon
58
Immatics
IMTX
$1.32B
$1.11M 0.26%
+105,000
New +$967K
ITOS
59
DELISTED
iTeos Therapeutics
ITOS
$1.08M 0.26%
98,560
– –
STIM icon
60
Neuronetics
STIM
$166M
$910K 0.22%
313,717
– –
ORIC icon
61
Oric Pharmaceuticals
ORIC
$1.4B
$670K 0.16%
+72,797
New +$526K
ACRV icon
62
Acrivon Therapeutics
ACRV
$74M
$646K 0.15%
131,351
+54,499
+71% +$288K
NVRO
63
DELISTED
NEVRO CORP.
NVRO
$603K 0.14%
28,000
– –
CGEN icon
64
Compugen
CGEN
$228M
$406K 0.1%
205,202
– –
MASI
65
DELISTED
Masimo
MASI
$352K 0.08%
3,000
– –
ADAP
66
DELISTED
Adaptimmune Therapeutics
ADAP
$278K 0.07%
351,064
– –
VIGL
67
DELISTED
Vigil Neuroscience
VIGL
$243K 0.06%
71,815
-100,493
-58% -$517K
ELEV
68
DELISTED
Elevation Oncology
ELEV
$242K 0.06%
450,000
– –
VTGN icon
69
VistaGen Therapeutics
VTGN
$12.8M
$215K 0.05%
+41,886
New +$159K
SPRO icon
70
Spero Therapeutics
SPRO
$73M
$184K 0.04%
125,000
– –
CMPX icon
71
Compass Therapeutics
CMPX
$387M
$182K 0.04%
116,882
– –
KPTI icon
72
Karyopharm Therapeutics
KPTI
$48M
$167K 0.04%
12,845
– –
MLYS icon
73
Mineralys Therapeutics
MLYS
$2.41B
$131K 0.03%
+15,200
New +$119K
KNTE
74
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$119K 0.03%
50,000
-55,179
-52% -$97.7K
INGN icon
75
Inogen
INGN
$164M
$82.3K 0.02%
15,000
– –
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, DAFNA Capital Management held 82 positions worth $417M, up 30% from $321M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management's Q4 2023 filing shows 7 new, 14 increased, 24 reduced and 6 closed positions. Its largest new stake was Sage Therapeutics: 245,000 shares worth $5.31M. The largest sale was Blueprint Medicines, an estimated $8.98M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier.

  • DAFNA Capital Management's largest Q4 2023 buy was Sage Therapeutics: 245,000 shares worth $5.31M.
  • DAFNA Capital Management added most to Syndax Pharmaceuticals in Q4 2023, an estimated $4.37M increase.
  • DAFNA Capital Management's biggest Q4 2023 reduction was Blueprint Medicines, cutting an estimated $8.98M.
  • DAFNA Capital Management fully exited Nurix Therapeutics in Q4 2023, selling an estimated $4.38M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $417M portfolio in Q4 2023.
  • DAFNA Capital Management opened 7 new positions and closed 6 in Q4 2023.
  • DAFNA Capital Management's portfolio value rose 30% quarter-over-quarter to $417M.

Based on DAFNA Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.